Top

Published in:

Open Access 01-12-2018 | Research

KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study

Authors: Mustafa A. El Sherbini, Amal A. Mansour, Maha M. Sallam, Emtiaz A. Shaban, Zeinab A. Shehab ElDin, Amr H. El-Shalakany

Published in: Journal of Ovarian Research | Issue 1/2018

Abstract

Background

KLK10 exon 3 hypermethylation correlated to tumor-specific lack of KLK10 expression in cancer cell lines and primary tumors. In the present study we investigate the possible role of KLK10 exon 3 methylation in ovarian tumor diagnosis and prognosis.

Results

Qualitative methylation-specific PCR (MSP) results did not show statistically significant differences in patient group samples (normal and tumor) where all samples were positive only for the unmethylated-specific PCR except for two malignant samples that were either doubly positive (serous carcinoma) or doubly negative (Sertoli-Leydig cell tumor) for the two MSP tests. However, KLK10 exon 3 unmethylated PCR product concentration (ng/μl) showed statistically significant differences in benign and malignant patient group samples; mean ± SD (n): tumor: 0.077 ± 0.035 (14) and 0.047 ± 0.021 (15), respectively, p-value = 0.011; and normal: 0.094 ± 0.039 (7) and 0.046 ± 0.027 (6), respectively, p-value = 0.031. Moreover, ROC curve analysis of KLK10 exon 3 unmethylated PCR product concentration in overall patient group samples showed good diagnostic ability (AUC = 0.778; p-value = 0.002). Patient survival (living and died) showed statistically significant difference according to preoperative serum CA125 concentration (U/ml); median (n): 101.25 (10) and 1252 (5), respectively, p-value = 0.037, but not KLK10 exon 3 unmethylated PCR product concentration (ng/μl) in overall malignant patient samples; mean ± SD (n): 0.042 ± 0.015 (14) and 0.055 ± 0.032 (7), p-value = 0.228.

Conclusion

To the best of our knowledge, this is the first report on KLK10 exon 3 unmethylated PCR product concentration as potential early epigenetic diagnostic marker in primary ovarian tumors. Taken into account the limitations in our study (small sample size and semi-quantitative PCR product analysis) further studies are strongly recommended.

Wallace K, Grau MV, Levine AJ, Shen LL, Hamdan R, Chen XL, Gui JA, Haile RW, Barry EL, Ahnen D, McKeown-Eyssen G, Baron JA, Issa JPJ. Association between folate levels and CpG Island Hypermethylation in normal colorectal mucosa. Cancer Prev Res (Phila). 2010;3:1552–64.CrossRef

Bird A, Tate P, Nan X, Campory J, Meehan R, Cross S, Tweedie S, Charlton J, Macleod D. Studies of DNA methyaltion in animals. J Cell Sci. 1995;Suppl 19:37–9.CrossRef

Bird AP. Functions of DNA methylation in vertebrates. Cold Spring Harb Symp Quant Biol. 1993;58:281–5.CrossRefPubMed

Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013; https://doi.org/10.1186/gb-2013-14-10-r115.

Miller C, Sweatt J. Covalent modification of DNA regulates memory formation. Neuron. 2007;53(6):857–69. https://doi.org/10.1016/j.neuron.2007.02.022.CrossRefPubMed

Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. Mol Biol. 1987;196:261–82.CrossRef

Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet. 2009;10(11):805–11.CrossRefPubMedPubMedCentral

Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J Cell Physiol. 2007;213:384–90.CrossRefPubMed

Costello JF, Plass C. Methylation matters. J Med Genet. 2001;38(5):285–303.CrossRefPubMedPubMedCentral

10.

Balgkouranidou I, Triantafyllou P, Theodoropoulos C, Tsaroucha EG, Kaklamanis L, Lianidou E. Prognsotic significance of DNA methylation markers in tissue and corresponding cell-free circulating DNA in plasma of NSCLC patients, vol. 2009. Denver: AACR 2009. 100st Annual Meeting of American Association of Cancer Research (AACR).

11.

Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun. 2000;276(1):125–33.CrossRefPubMed

12.

Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 1996;56(14):3371–9.PubMed

13.

Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53(8):1423–32.CrossRefPubMed

14.

Luo LY, Grass L, Diamandis EP. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin Chim Acta. 2003;337(1–2):115–26.CrossRefPubMed

15.

Chow TF, Crow M, Earle T, El-Said H, Diamandis EP, Yousef GM. Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol Chem. 2008;389(6):731–8.CrossRefPubMed

16.

Hu J, Lei H, Fei X, Liang S, Xu H, Qin D, Wang Y, Wu Y, Li B. NES1/KLK10 gene represses proliferation, enhances apoptosis and downregulates glucose metabolism of PC3 prostate cancer cells. Sci Rep. 2015; https://doi.org/10.1038/serp17426.

17.

Dhar S, Bhargava R, Yunes M, Li B, Goyal J, Naber SP, Wazer DE, Band V. Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res. 2001;7(11):3393–8.PubMed

18.

Luo LY, Rajpert-De Meyts ER, Jung K, Diamandis EP. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumor suppressor gene in normal and malignant testicular tissue. Br J Cancer. 2001;85(2):220–4.CrossRefPubMedPubMedCentral

19.

Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana V, Luo LY, Diamandis EP. Immunohistochemical localization of human kalikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003;6(3):223–7.CrossRefPubMed

20.

Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC Jr, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinoma. Gynecol Oncol. 2003;90(1):44–50.CrossRefPubMed

21.

Talieri M, Alexopoulou DK, Scorilas A, Kypraios D, Arnogiannaki N, Devetzi M, Patsavela M, Xynopoulos D. Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol. 2011;32(4):737–44.CrossRefPubMed

22.

Rückert F, Hennig M, Petraki CD, Wehrum D, Distler M, Denz A, Schröder M, Dawelbait G, Kalthhoff H, Saeger HD, Diamandis EP, Pilarsky C, Grützmann R. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer. 2008;99(9):1484–92.CrossRefPubMedPubMedCentral

23.

Li B, Goyal J, Dhar S, Dimri G, Evron E, Sukumar S, Wazer DE, Band V. CpG methylation as a basis for breast tumor-specific loss of NES1/KLK10 expression. Cancer Res. 2001;61(21):8014–21.PubMed

24.

Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Barrios M, Andreu EJ, Prosper F, Heiniger A, Torres A. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia. 2004;18(2):362–5.CrossRefPubMed

25.

Sidiropoulos M, Pampalakis G, Sotiropoulo G, Katsaros D, Diamandis EP. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 2005;26(6):324–36.CrossRefPubMed

26.

Zhang Y, Song H, Miao Y, Wang R, Chen L. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci. 2010;101(4):934–40.CrossRefPubMed

27.

El Sherbini MA, Sallam MM, Shaban EA, El-Shalakany AH. Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer. Int J Gynecol Cancer. 2011;21(4):625–32.CrossRefPubMed

28.

Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for Folate’s role. Adv Nutr. 2012;3:21–38. https://doi.org/10.3945/an.111.000992.CrossRefPubMedPubMedCentral

29.

Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.CrossRefPubMedPubMedCentral

30.

Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann Oncol. 2009;20(6):1020–5.CrossRefPubMed

31.

van Vlodrop IJH, Niessen HE, Derks S, Baldewijns MM, van Criekinge W, Herman JG, van Engeland M. Analysis of promoter CpgG island hypermethylation in cancer: location, location, location! Clin Cancer Res. 2011;17(13):4225–31.

32.

Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 1998;58(21):4782–6.

33.

Huang W, Tian X-L, Wu Y-L, Zhong J, Yu L-F, Hu SP, Li B. Suppression of gastric cancer growth by baculovirus vector-mediated transfer of normal epithelial cell specific-1 gene. World J Gastroenterol. 2008;14:5810–5.CrossRefPubMedPubMedCentral

34.

Pépin D, Shao ZQ, Huppé G, Wakefield A, Chu CW, Sharif Z, Vanderhyden BC. Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. PLoS One. 2011;6(11):e26075. https://doi.org/10.1371/journal.pone.0026075.CrossRefPubMedPubMedCentral

35.

Ewan King L, Li X, Cheikh Saad Bouh K, Pedneault M, Chu CW. Human kallikrein 10 ELISA development and validation in breast cancer sera. Clin Biochem. 2007;40(13–14):1057–62.CrossRefPubMed

36.

Jiao X, Lu H-J, Zhai M-M, Zhang D-P. Overexpression of kallikrein gene 10 is a biomarker for predicting poor prognosis in gastric cancer. World J Gastroenterol. 2013;19(48):9425–31.CrossRefPubMedPubMedCentral

37.

Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4:876–90. https://doi.org/10.1038/nrc1474.CrossRefPubMed

38.

Xu H, Podolsky RH, Ryu D, Wang X, Su S, Shi H, George V. A method to detect differentially methylated loci with next-generation sequencing. Genet Epidemiol. 2012;37(4):377–82.CrossRef

39.

Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet. 1988;78:151–5.CrossRefPubMed

40.

Rideout WM, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990;249(4974):1288–90.CrossRefPubMed

Title: KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study
Authors: Mustafa A. El Sherbini
Amal A. Mansour
Maha M. Sallam
Emtiaz A. Shaban
Zeinab A. Shehab ElDin
Amr H. El-Shalakany
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-018-0407-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study

Abstract

Background

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Does a poor-quality embryo have an adverse impact on a good-quality embryo when transferred together?

Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients

Identification of core genes in ovarian cancer by an integrative meta-analysis

Is the aging human ovary still ticking?: Expression of clock-genes in luteinized granulosa cells of young and older women

Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, Embase and Google scholar

Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study